Anti-Human CD79B Reference Antibody (Polatuzumab, RUO) (HW431016)

Name: Anti-Human CD79B Reference Antibody (Polatuzumab, RUO)
Brand: abinScience
SKU: HW431016
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HW431016
Description	Polatuzumab (HW431016) is a research-grade recombinant antibody targeting CD79B. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG1-kappa
Système d'expression	Mammalian cells
Cible	B-cell-specific glycoprotein B29, CD79B, B-cell antigen receptor complex-associated protein beta chain, Ig-beta, B29, Immunoglobulin-associated B29 protein, IGB, CD79b
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P40259
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	ACD79B-VCMMAE, DCDS4501A, FCU2711, RO5541077-000, polatuzumabvedotin-piiq, 1313206-42-6
Contexte	B-cell antigen receptor complex-associated protein beta chain (CD79B) is a ~26 kDa protein. Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. CD79B is the therapeutic target of polatuzumab vedotin (Polivy).
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (HyHEL-10) (HV080407) Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)